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Abstract
Among long-stay critically ill patients in the adult intensive care unit (ICU), there are often marked changes in the complexity 
of the gut microbiota. However, it remains unclear whether such patients might benefit from enhanced surveillance or from 
interventions targeting the gut microbiota or the pathogens therein. We therefore undertook a prospective observational study 
of 24 ICU patients, in which serial faecal samples were subjected to shotgun metagenomic sequencing, phylogenetic profiling 
and microbial genome analyses. Two-thirds of the patients experienced a marked drop in gut microbial diversity (to an inverse 
Simpson’s index of <4) at some stage during their stay in the ICU, often accompanied by the absence or loss of potentially ben-
eficial bacteria. Intravenous administration of the broad-spectrum antimicrobial agent meropenem was significantly associ-
ated with loss of gut microbial diversity, but the administration of other antibiotics, including piperacillin/tazobactam, failed to 
trigger statistically detectable changes in microbial diversity. In three-quarters of ICU patients, we documented episodes of gut 
domination by pathogenic strains, with evidence of cryptic nosocomial transmission of Enterococcus faecium. In some patients, 
we also saw an increase in the relative abundance of apparent commensal organisms in the gut microbiome, including the 
archaeal species Methanobrevibacter smithii. In conclusion, we have documented a dramatic absence of microbial diversity and 
pathogen domination of the gut microbiota in a high proportion of critically ill patients using shotgun metagenomics.
DATA SummARy
Metagenome sequences have been deposited in the Sequence 
Read Archive under Bioproject reference PRJNA533528: 
https://www. ncbi. nlm. nih. gov/ bioproject/ 533528.
InTRoDuCTIon
Interest has recently focused on the gut microbiota in long-stay 
patients on the adult intensive care unit (ICU) [1–3]. Unfor-
tunately, many life-saving measures applied to ICU patients 
potentially have negative impacts on the gut microbiota 
– examples include assisted ventilation, enteric feeds and a 
range of medications, including broad-spectrum antibiotics, 
proton pump inhibitors, inotropes and opioids [4–6]. In 
recent years, interest has grown in protecting or restoring 
the integrity of the gut microbiome in ICU patients, using 
ecological approaches such as probiotics or faecal microbiota 
transplants [7–18]. Similarly, surveillance of pathogens and 
of antimicrobial resistance in the gut of critically ill patients 
has potential benefit in predicting infection and guiding treat-
ment or infection control measures [19–21]. However, in the 
absence of high-precision approaches to the surveillance of 
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complex microbial communities, it remains unclear which 
ICU patients might benefit from interventions affecting the 
gut microbiota and how such interventions should be targeted 
for optimum effect.
Fortunately, recent advances in sequencing and bioinformatics 
have made shotgun metagenomics an attractive approach 
in precision medicine [22, 23]. We therefore undertook a 
prospective observational study of 24 ICU patients, in which 
serial faecal samples were subjected to shotgun metagenomic 
sequencing, phylogenetic profiling and microbial genome 
analyses, with the aims of evaluating the utility of shotgun 
metagenomics in long-stay ICU patients, documenting the 
dynamics of the gut microbiota in this context and deter-
mining how it is affected by relevant clinical and demographic 
factors.
mETHoDS
Study design and human subjects
Queen Elizabeth Hospital Birmingham is a university teaching 
hospital serving a population of approximately 1.5 million 
with a wide range of tertiary services, including solid organ 
and bone marrow transplantation. Patients were enrolled for 
study participation if they were aged over 18 years and had 
been admitted to the ICU within the previous 72 h and were 
expected to remain there for more than 48 h. Patients were 
considered to be evaluable if their first stool sample and at 
least one subsequent sample were collected on the ICU.
Patient information was collected on a case report form, which 
included information on gender, age, reason for admission, 
severity of disease scores, length of hospital stays prior to ICU 
admission, current antibiotic therapy, blood markers, details 
of nutrition, drugs and relevant clinical microbiology results. 
The study started in May 2017 and ended in February 2018, 
when data and specimen collection for the 30th participant 
had been completed.
Sample collection, storage and DnA extraction
The first faecal sample passed each calendar day by each 
enrolled patient on the ICU was collected and sent to the 
research team. Stool samples were aliquoted and then frozen 
at −20 °C as soon as possible after collection. They were then 
shipped frozen to the Quadram Institute in Norwich, where 
they were stored at −80 °C. Time and date of collection and 
transport was noted. Faecal samples were destroyed at the 
end of the study. Around 0.1 to 0.2 g of frozen faecal sample 
was used for DNA extraction. The extraction was carried out 
using the FastDNA SPIN Kit for Soil (MP Biomedicals, CA, 
USA) according to the manufacturer’s instructions, except 
that 100 µl rather than 50 µl of DES elution buffer was used 
in the final elution.
Samples from extra-intestinal sites were collected when 
indicated on clinical grounds and processed by the hospital’s 
clinical microbiology laboratory using standard diagnostic 
procedures.
Shotgun metagenomic sequencing
The DNA concentration was normalized using Qubit 4 (Invit-
rogen, Thermo Fisher, MA, USA) and sequencing libraries 
were prepared using the Nextera XT library preparation kit 
(Illumina). The DNA was fragmented, tagged, cleaned and 
normalized according to the manufacturer’s recommenda-
tions. The quality of the final pooled library was evaluated 
using Agilent 2200 Tape Station (Agilent) and the concen-
tration was measured using Qubit 4 (Invitrogen, Thermo 
Scientific, MA, USA). Libraries were sequenced in batches 
on a NextSeq 550 using a high-output flow cell delivering 
150 bp paired-end reads. The libraries were sequenced to a 
sequencing depth of ∼2 Gbp per sample.
Reads from the sequencer were uploaded onto virtual 
machines provided by the Medical Research Council (MRC) 
Cloud Infrastructure for Microbial Bioinformatics (CLIMB) 
project using BaseMount [24, 25]. Initially, the sequences 
were assessed for quality using FastQC (version 0.11.5) and 
SeqKit with the parameter ‘stats’ [26, 27]. Quality filtering was 
performed using Trimmomatic (version 0.35) with default 
parameters [28]. Trimmomatic’s Illuminaclip function was 
used to remove Illumina adapters. Human sequences were 
removed by mapping reads towards the human genome, 
Impact Statement
While much work on the gut microbiota looks at subtle 
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and disease, here we show that the gut microbiota in the 
critically ill represents a worst-case scenario, where 
the usual rich and versatile microbial community of 
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3Ravi et al., Microbial Genomics 2019;5
Hg19, using BowTie 2 version 2.3.4.1 [29]. SAMtools [30] 
view was used with parameters (-f 12 -F 256) to extract 
unmapped reads (forward and reverse) and reads that are 
not primary alignments respectively. BEDtools bamtofastq 
was used to convert resulting BAM to FASTQ files [31]. Then, 
these sequences were deposited in the Sequence Read Archive 
under reference PRJNA533528.
Taxonomic profiling and statistical analysis
Forward and reverse paired reads were merged for each 
sample and fed as input to MetaPhlAn2 v2.7.7, which was 
used for taxonomic assignment of reads in each sample [32]. 
Metaphlan2 output was merged using the Python script 
merge_ metaphlan_ tables. py. A species-only abundance table 
(Table S1, available in the online version of this article) was 
created using Text Wrangler v5.5.2. Species that occurred 
only once and species with a relative abundance below 1 % in 
the whole dataset were discarded. This abundance data table, 
along with the metadata, was used for diversity analyses.
Alpha diversity was assessed using the inverse Simpson’s 
index calculated from the MetaPhlAn2 output using the 
vegan package (version 2.5–4) in R (version 3.5.2) [33]. Use 
of meropenem and piperacillin/tazobactam was coded indi-
vidually because of their clinical importance and high use 
in our dataset, while all other antimicrobials were grouped 
together in a single variable ‘other antimicrobials’ for the final 
multivariable analysis. To account for the long-term effects of 
antibiotics on microbial diversity and the absence of data on 
when antibiotics were started, antibiotic use variables were 
coded at each sampling point into one of four levels: no use, 
starting use, ongoing use and historic use. Episodes were clas-
sified as ‘starting’ if the antibiotic was started on the same day 
the sample was taken; ‘ongoing’ if the antibiotic was still being 
administered on the day of a sample being taken; ‘historic’ 
if the antibiotic had been used prior to the date of sample 
collection but was no longer being administered.
Linear mixed models were used to estimate the fixed effects 
on alpha diversity of time in relation to ICU admission, anti-
biotic use, time of sample storage and health status measured 
by sequential organ failure assessment (SOFA) score, and age 
and sex of the patient. The nlme package (version 3.1–137) 
in R (version 3.5.2) was used to estimate all models [33, 34]. 
For the mixed effects regression model, data from 228 samples 
were included in the final analysis. Nine samples were 
excluded because the SOFA score was missing. The dataset 
included 42 samples where meropenem was administered 
and 44 where piperacillin/tazobactam was administered. 
Random patient-level effects on intercept and slope (linear 
change in diversity over time) were included in the model. An 
auto-regressive correlation structure (AR1) in discrete time 
was used to account for the residual autocorrelation due to 
longitudinal patient’s affect.
Subsampling of metagenome sequences was performed using 
Seqtk (https:// github. com/ lh3/ seqtk) by adding the parameter 
‘sample’. Metaphlan2 was rerun for the subsampled reads and 
the statistical analyses. Pairwise correlations between the 
diversity indices was analysed in Rstudio version 1.1.453.
metagenome-assembled genomes (mAGs)
For metagenomic binning, reads from each patient were 
co-assembled into contigs using MEGAHIT v1.1.3 [35]. Next, 
Anvi’o version 5.1 was used for mapping, binning, refining 
and visualizing the bins [36]. In brief, ‘anvi-gen-contigs-
database’ was used with default settings to profile the contigs 
using Prodigal v2.6.3 and identify open reading frames [37]. 
Then, ‘anvi-run-hmms’ was used with default settings to iden-
tify bacterial, archaeal and fungal single copy gene collections 
using HMMER [38] and ‘anvi-run-cogs’ was used to predict 
gene functions in the contigs by using the National Center for 
Biotechnology Information’s (NCBI’s) Cluster of Orthologous 
Groups database. The taxonomy of the contigs was predicted 
using Centrifuge v1.0.3-beta [39] and added to the database 
using the ‘anvi-import-taxonomy-for-genes’ function. The 
reads from each sample of the respective patient were mapped 
to their corresponding co-assembled contigs using Bowtie 
2 v2.3.4.1 and converted into sorted and indexed bam files 
using Samtools v1.9. Then, ‘anvi-profile’ was used to profile 
each bam file to estimate coverage and detection statistics 
for every contig in each sample. Next, ‘anvi-merge’ was used 
to combine the profiles of each sample and create a merged 
anvi’o profile. Then, ‘anvi-interactive’ was used to interactively 
visualize the distribution of the bins and identify MAGs.
We classified a genome bin as a MAG if it was more than 80 % 
complete and its redundancy was below 10 %. The complete-
ness and redundancy for bacterial MAGs were assessed using 
‘anvi-run-hmm’ with Anvi’o’s default HMM profiles associated 
with 139 single-copy genes [36]. Each bin was then refined 
using ‘anvi-refine’ based on tetranucleotide frequency, mean 
coverage, completion and redundancy. The program ‘anvi-
summarize’ was used to generate an HTML output stat and 
FASTA file with the refined MAGs. To confirm completion 
and redundancy of the MAGs, CheckM v1.0.13 was used [40]. 
To recover MAGs for the fungal genomes, ‘anvi-run-hmms’ 
was used with BUSCO [41], a collection of 83 eukaryotic 
single-copy genes, while ‘anvi-compute-completeness’ was 
used to identify completion and ‘anvi-interactive’ was used 
to recover the MAGS.
For low-abundance pathogens that had been identified 
by MetaPhlAn2 but could not be recovered using Anvi’o, 
we constructed sets of completed taxon-specific reference 
genomes for each potential pathogen. Reference sequences 
were downloaded using the ‘ncbi-genome-download’ script 
[42]. We then mapped the metagenome from each sample 
against the relevant reference dataset using BowTie 2 version 
2.3.4.1 [29]. The mapped reads were recovered using BEDtools 
bamtofastq and assembled into contigs using SPAdes (version 
3.11.1) [43] and annotated using Prokka (version 1.12) [44]. 
Completion and contamination of these MAGs were assessed 
using CheckM. The coverage of the resulting draft genome 
sequences was calculated after mapping reads back to the 
assemblies using BowTie 2 and visualized with Qualimap2 
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Table 1. Clinical features and gut microbial ecology of ICU patients
Patient Age, sex Clinical features Minimum ISI* Peak pathogens in gut and % 
abundance†
Clinical samples with 
same pathogen
2 64, F Subarachnoid haemorrhage 3.9 K. pneumoniae, 17 %
4 75, M Aortic aneurysm repair 1.5 E. coli, 80 %
8 59, M Subarachnoid haemorrhage 2.2 None
10 55, M Multiple trauma 5.3 None
24 59, M Drug-induced hepatitis 2.4 E. coli, 62 %
25 46, M Subarachnoid haemorrhage; alcoholic 
liver disease
1.0 E. faecium, 99 %; E. coli, 38 % Urine
29 80, M Subcapsular haematoma; liver cancer 6.2 Enterococcus faecium, 30 %
31 43, M Subarachnoid haemorrhage; alcoholism 3.1 P. mirabilis, 18 % Sputum
35 49, M Lung transplant 1.0 C. albicans, 82 %
36 30, M Multiple trauma 1.9 E. coli, 68 %
37 47, M Multiple trauma 3.1 None
38 47, M Insertion of left ventricular assist device 1.0 C. albicans, 77 %; E. faecium, 38 %; E. 
cloacae, 29 %
Sputum, blood
41 61, M Oesophagectomy 1.5 E. faecium, 81 %
45 63, M Multiple trauma 5.2 None
46 25, M Chest infection 4.0 E. faecalis, 29 %; E. coli, 24 % Urine
47 46, M Subdural haemorrhage; hepatitis C; 
alcoholism
4.8 E. coli, 10 %
49 65, F Intracerebral haematoma 10.2 None
51 78, M ST-elevation myocardial infarction 1.2 E. faecium, 89 %
52 54, F Aortic valve repair; Marfan syndrome 2.1 E. faecium, 69 %
53 40, F Anaemia; end-stage renal disease 1.0 E. faecium, 99 %; Klebsiella oxytoca, 24 % Urine
54 66, M Alcoholic liver disease 2.4 Enterococcus raffinosus, 63 %; E. faecium, 
44 %
55 66, F Subdural haemorrhage 3.6 E. faecium, 49 %
57 84, M Cardiac arrest; cardiomyopathy 5.6 None
59 77, M Subdural haemorrhage 4.8 E. faecalis, 18 %
*, lowest microbial diversity in serial faecal samples from each patient, as reflected by inverse Simpson’s index.
†, peak relative abundance of potential pathogens in serial faecal samples from each patient.
[45]. To confirm species identity, average nucleotide identity 
was calculated from blast searches [46] or by using the 
online ANI/AAI matrix tool [47].
Resistance genes in the MAGs were identified using ABRi-
cate v0.8.10 (https:// github. com/ tseemann/ abricate) to 
find matches to resistance genes in the ResFinder database 
(consisting of 3021 sequences, updated on 20 October 2018) 
and the CARD database (consisting of 2237 sequences, 
updated on 20 October 2018) [42]. Default parameters were 
used for running ABRicate and the reports from the individual 
samples were compiled using the ‘—summary’ option. Only 
genes that had 100 % coverage to reference genes were only 
considered. Candida albicans MAGs were annotated using 
Prokka version 1.12 and the gene ERG11, encoding lanosterol 
14-alpha demethylase, was extracted and searched for point 
mutations conferring resistance to fluconazole, itraconazole 
and/or voriconazole. For the identification of the mutations, 
blastn in the Mycology Antifungal Resistance Database 
(http://www. mardy. net/) was used.
For phylogenetic analyses of the MAGs, multi-locus 
sequence typing was performed using Torsten Seeman’s mlst 
program (https:// github. com/ tseemann/ mlst). Complete 
E. faecium genomes of ST 80 were downloaded using the 
‘ncbi-genome-download’ script (https:// github. com/ kblin/ 
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Fig. 1. Pathogen domination of the gut microbiota. Timelines for patients showing pathogen domination, with relative abundance 
assessed by percentage of reads mapping to MAGs. Various antibiotics were given for treatment purposes during the study period.
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Table 2. Gut microbial diversity and clinical factor coefficients from a mixed effects regression model measuring the association between faecal 
microbial alpha diversity (inverse Simpson’s index) and demographics and clinical factors. Total of n=228 samples included in the analysis
Unit/level n/mean (sd) Coefficient 95 % CI P-value
Age Per year 54.6 (14.8) 0.03 (−0.03, 0.09) 0.382
Sex Male vs female 170 −0.14 (−2.40, 2.12) 0.897
Time since admission Per day 18.1 (12.5) −0.03 (−0.10, 0.04) 0.421
Meropenem No use 114 0 Reference
Ongoing 42 −1.82 (−3.40, 0.25) 0.024*
Starting 7 −1.30 (−3.03, 0.44) 0.143
History 65 −1.29 (−2.92, 0.35) 0.122
Piperacillin/tazobactam No use 51 0 Reference
Ongoing 44 0.66 (−1.09, 2.42) 0.456
Starting 4 1.50 (−0.87, 3.87) 0.214
History 129 0.83 (−0.92, 2.58) 0.350
Other antimicrobial No use 32 0 Reference
Ongoing 55 −1.16 (−3.12, 0.79) 0.242
Starting 8 −0.03 (−2.15, 2.09) 0.980
History 133 −0.99 (−2.83, 0.85) 0.290
Bristol stool index 1–3 9 0 Reference
4 28 −0.54 (−2.25, 1.17) 0.536
5 48 0.32 (−1.40, 2.04) 0.715
6 75 −0.19 (−1.83, 1.46) 0.823
7 62 −0.70 (−2.41, 1.02) 0.423
Missing 6 0.04 (−2.22, 2.30) 0.975
SOFA score Per point 6.1 (3.4) −0.15 (−0.31, 0.01) 0.065
SOFA score, sequential organ failure score; higher values, greater morbidity.
*P<0.05.
n: number of samples with each level of covariate; sd: standard deviation.
ncbi- genome- download). There were eight complete genomes 
in the taxonomy database. Core-genome single-nucleotide 
polymorphisms (SNPs) in the MAG and completed genomes 
from E. faecium were identified using Snippy v3.1 [29] and 
were then used to create a phylogeny with RAxML with a 100 
rapid bootstrap analyses with the GTR-CAT model. The tree 
was rooted using the E. faecium DO complete genome (https://
www. ncbi. nlm. nih. gov/ genome/ 871? genome_ assembly_ id= 
169556). Genome comparisons between closely related MAGs 
were performed using blast Ring Image Generator [48].
Pathogen culture
For the isolation of Escherichia coli, C. albicans and E. faecium, 
two separate aliquots (0.1–0.2 g) of each stool sample were 
loaded into 1.5 ml microcentrifuge tubes under aseptic 
conditions. One millilitre of physiological saline (0.85%) was 
added and the saline–stool samples were vortexed for 2 min at 
maximum speed to homogenize the samples completely. The 
homogenized samples were taken through eight 10-fold serial 
dilutions and 100 µl aliquots from each dilution were dispensed 
onto tryptone–bile–X–glucoronide agar, Sabouraud dextrose 
agar and Slanetz and Bartley medium (Oxoid). Both aliquots 
were plated in triplicate. The sample suspensions were spread 
on the plates using the cross-hatching method for confluent 
growth. Inoculated plates were incubated at 37 °C for 18–24 h 
(for tryptone–bile–X–glucoronide agar and Sabouraud dextrose 
agar) or for 48 h on Slanetz and Bartley medium.
Following incubation, the plates were examined for growth. 
On tryptone–bile–X–glucoronide agar, raised blue–green 
colonies with entire margins were taken as being indicative 
of the growth of E. coli. On Sabouraud dextrose agar, raised 
white-to-cream entire colonies with yeast-like appearance 
were scored as Candida. On Slanetz and Bartley medium, 
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Fig. 2.  abundance of gut micro-organisms among patients who began meropenem during the study This heat map shows the top 50 
taxa by average relative abundance across the whole dataset. Greyscale shading of cells shows relative abundance: 0, no shading; 0–1 %, 
light grey; 1–10 %, mid-grey; >10 %, dark grey. Coloured shading of columns reflects meropenem use: no use, blank; ongoing use, dark 
blue; history of meropenem, light blue.
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smooth pink-to-red colonies with a whitish margin were 
indicative of the growth of Enterococcus. Colonies were 
counted on the dilution plate that showed the highest number 
of discrete colonies and the colony count for each of the trip-
licate plates per dilution was recorded.
High-throughput qPCR
Real-time quantitative PCR was performed using the Light-
Cycler 480 (Roche, Germany) apparatus. Universal bacterial 
primers [43, 49] were used to determine the 16S rRNA copy 
number. Real-time PCR analyses were performed using 
LightCycler 480 SYBR Green 1 Master Mix (Roche, Germany) 
following the manufacturer’s instructions and at an annealing 
temperature of 56 °C. The DNA concentration was measured 
in a Qubit Broad Range assay kit (Invitrogen, Thermo Fisher, 
MA, USA) and the concentration was normalized to 5 ng 
µl−1. A 10 µl reaction was used with 0.1 mM of the universal 
primers. DNase-free water was used for negative controls. 
Standard curves were generated from E. coli standards 
normalized to 5 ng µl−1 and the copy numbers of the samples 
were calculated using standard curves. In order to assess the 
primer specificity, melt curve analyses were performed after 
qPCR using Fluidigm melting curve analysis software (http:// 
fluidigm- melting- curve- analysis. software. informer. com/).
RESuLTS
We initially recruited 30 serially recruited adult patients who 
were expected to stay on the ICU for >48 h. As is typical of ICU 
patients, the study population was heterogeneous, including 
patients with little or no previous medical history (e.g. suffering 
from trauma or intracranial haemorrhage), as well as individ-
uals with complex and chronic clinical conditions and varying 
immune function. A set of 24 long-stay ICU patients who 
provided more than 5 samples was selected for further study 
(Table 1; Table S2).
To track the gut microbial dynamics of individual patients, we 
performed metagenomic sequencing of serial faecal samples 
(Table S1), followed by community analysis to determine the 
relative abundance of microbial species. The inverse Simpson’s 
index was calculated to assess microbial diversity (Table S3). 
Median time to receipt of a sample (where timings were avail-
able) from collection to storage was 2.6 h; 70 % of samples 
were received within 6 h and 87 % within 12 h. We found no 
association between changes in microbial diversity and time to 
receipt of sample or with the proportion of human reads in the 
sample (Table S4).
Loss of gut microbial diversity and pathogen 
domination with meropenem
In two-thirds of patients, we saw a fall in diversity at some 
stage during their stay in ICU to an inverse Simpson’s index 
of <4 (Table 1; Table S3). An equivalent loss of microbial 
diversity was seen when sequence datasets were down-
sampled to two million or to one million reads, showing 
that this is not the result of shallow or uneven sampling 
(Fig. S1). In a third of our patients, diversity fell, in at least 
one sample, to a precipitously low level, with an inverse 
Simpson’s index of <2, echoing findings from previous 
studies that used 16S rRNA gene amplicon sequencing 
[50, 51]. A fall in diversity was typically accompanied by 
domination in terms of the relative abundance of a single 
micro-organism in the sample.
In 75 % of the long-stay ICU patients, we saw a marked 
increase in the relative abundance of individual patho-
gens in stool samples. These included ESKAPE pathogens 
(Enterococcus faecium, Klebsiella pneumoniae, Enterobacter 
cloacae), other species of Enterobacteriaceae (E. coli, Kleb-
siella oxytoca, Proteus mirabilis) and the fungal pathogen C. 
albicans. During these episodes of pathogen domination, 
particularly for E. faecium, E. coli and C. albicans, the relative 
abundance of the pathogen often exceeded 50 % of sequence 
reads – in one patient, patient 53, in seven consecutive 
samples, >80 % of evaluable sequences were assigned to E. 
faecium (Fig. 1).
We found no statistically significant associations between 
microbial diversity and stool consistency (Bristol stool index) 
or SOFA score (Table 2). All but one of the ICU patients 
received antimicrobial chemotherapy at some point during 
their ICU stay, most commonly with the broad-spectrum 
agents piperacillin/tazobactam or meropenem. Surprisingly, 
piperacillin/tazobactam failed to trigger statistically detect-
able changes in microbial diversity, despite the apparent sensi-
tivity of gut commensals to such agents [6]. However, current 
use of the intravenous agent meropenem was significantly 
associated with loss of gut microbial diversity and domination 
of pathogens in our ICU patients [change in inverse Simpsons 
index= −1.8, 95 % confidence interval (CI)= −3.4 to −0.25; 
P=0.024; Table 2). Similarly profound ecological changes have 
been reported in a study involving healthy volunteers given 
meropenem [52].
Impact on gut commensals
Antibiotics are known to provoke overgrowth in the gut of 
microbial species not known to be pathogens [52–54]. We 
saw the relative abundance of the archaeon Methanobrevi-
bacter smithii exceed 10 % of reads in nine ICU patients. 
Quantitative PCR investigations, confirming that bacterial 
biomass did not change over time, suggest that this reflects 
an increase in abundance of this archaeon in real terms 
(Fig. S2), even though this organism always remained a 
minority component of the microbiota. Interestingly, recent 
publications have shown that the cultural and ecological 
requirements for M. smithii are far simpler than previously 
thought, supported even by individual species of bacterial 
pathogens or commensals [55–57] Furthermore, isolation 
of this organism from vaginal and urine samples raises the 
question of whether it should always be considered a harm-
less commensal [57, 58].
Other apparent commensals showing rises in relative abun-
dance to >50 % include Streptococcus thermophilus, Alistipes 
onderdonkii, Bifidobacterium longum, an unnamed species 
from Erysipelotrichaceae, Ruminococcus torques and an 
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unclassified species of Subdoligranulum (Fig. 2; Table S1). 
We also observed reductions in the relative abundance of 
gut bacteria when comparing the sample with the highest 
diversity (typically first day in ICU) to the last sample for 
each patient (Table S5), with loss of Ruminococcus gnavus, 
R. torques, Faecalibacterium prausnitzii and Colinsella aero-
faciens evident in at least five patients.
mAGs and nosocomial transmission of pathogens
We obtained MAGs of the potential pathogens and used them 
to reconstruct pathogen biology and epidemiology, including 
multi-locus sequence types (Table S6). We found that 
pathogen blooms within an individual patient were typically 
clonal, i.e. caused by a single strain. Pathogens dominating 
the gut microbiota in ICU patients were also typically inher-
ently resistant to antibiotics or possessed genes associated 
with antimicrobial resistance – vancomycin-resistance genes 
were detected in two strains of E. faecium and aminoglycoside 
resistance genes in two strains of E. coli, one of which also 
encoded an extended-spectrum beta-lactamase (Table S7). 
Metagenomic surveys of resistance genes in samples typically 
reported profiles almost completely matching the resistance 
genes present in the dominating pathogen. However, we did 
detect in some samples genes associated with resistance to 
macrolides (mphA and msrC genes) and aminoglycosides 
(ant and aph genes) that were absent from any of our MAGs 
(Fig. S3).
Enterococcal blooms were seen in 11 patients. In six cases, 
the dominant strain belonged not just to the same species, E. 
faecium, but also to the same sequence type, ST80, which is a 
well-documented cause of nosocomial outbreaks across the 
globe [59–61]. Core phylogenetic analyses with the MAGs 
identified in this study and complete public E. faecium ST 
80 genomes from the NCBI database indicated that the E. 
faecium MAGs of patients 51, 54, 55 were closely related 
MAGs. The E. faecium MAGS of patients 51 and 54 differed 
by 39 SNPs and those of patients 51 and 55 differed by 142 
SNPs in their core genomes (Fig. S4). Interestingly, all three 
patients had overlapping stays in adjacent rooms on the ICU.
Quantification of pathogens
In several patients (patients 4, 24, 25, 41, 51, 53 and 55), 
we found that an increase in the relative abundance of 
sequences assigned to a bacterial pathogen (E. coli or E. 
faecium) occurred in association with an increase in total 
bacterial biomass (determined by qPCR) and/or an increase 
in pathogen abundance (determined by quantitative 
culture), confirming that pathogen abundance increased 
in absolute as well as in relative terms (Fig. S5). However, 
similar increases in the relative abundance of the fungal 
pathogen C. albicans in patients 35 and 38 were accom-
panied by a decrease in bacterial 16S rRNA copy number 
and a lack of increase in abundance on quantitative culture, 
suggesting that that apparent changes in the abundance of 
this fungal pathogen are best explained by loss of bacterial 
biomass.
DISCuSSIon
Here, we have shown the utility of applying shotgun 
metagenomics to ICU patients for surveillance of the gut 
microbiota, documenting the loss of gut microbial diversity 
and domination of the gut by drug-resistant pathogens. 
Our use of shotgun metagenomics confirms the results 
of previous studies on ICU patients using less powerful 
sequence-based approaches, linking loss of gut microbial 
diversity to adverse clinical outcomes and loss of coloni-
zation resistance [19–21, 50, 51, 62–69]. However, with 
shotgun metagenomics, we have been able to reconstruct 
informative metagenome-assembled genomes, allowing us 
to characterize pathogens, identify resistance determinants 
and document cryptic nosocomial transmission of a clone 
of E. faecium that colonized three patients.
It is well established that administration of antibiotics leads 
to loss of diversity in the gut microbiota [70–73]. Nonethe-
less, although all but one of our patients received antibiotics, 
we only saw a statistically significant loss of diversity – and 
marked loss of beneficial organisms – after the administration 
of meropenem. Similar profound and longstanding effects of 
this agent on gut microbial diversity have been documented 
in healthy adults [52]. Although we were unable to detect any 
effect of other antimicrobials, given the small sample size, we 
cannot rule out small but significant effects for less commonly 
used agents.
The contrast between the effect of meropenem and the 
apparent lack of effect of other broad-spectrum agents such 
as piperacillin/tazobactam suggests that pharmacokinetics 
plays a key role in determining impact on the gut micro-
biota and that there is scope for tailoring antibiotic regimes 
to spare the gut microbiota, building on previous studies 
confirming the low-risk status of ureidopenicillins such as 
piperacillin on the risk of Clostridioides difficile infection or 
colonization with vancomycin-resistant enterococci [74, 75].
We have used shotgun metagenomics to document domina-
tion of the gut microbiota by microbial pathogens in most 
ICU patients. Although from sequences alone, it is hard to 
determine whether increases in the relative abundance of 
pathogens reflect an increase in the biomass of pathogens or 
simply a loss of commensals [76, 77], we were able to use 
qPCR and microbial culture to confirm that, at least in some 
cases, there was a genuine increase in the absolute abundance 
of the pathogen.
In a quarter of our patients, in line with other similar attempts 
at sequence-based surveillance in vulnerable patients 
[19, 20], the same species of pathogen was isolated from 
clinical samples from outside the gut. However, as our clinical 
isolates were not subjected to genome sequencing, we cannot 
be certain that they belonged to the strains associated with 
domination of the gut.
Interestingly, we also saw episodes of ecological domination 
by apparent commensals. The significance of these episodes 
remains uncertain. A recent study has suggested that 
commensal bacteria carry diverse uncharacterized resistance 
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genes that contribute to their selection after antibiotic therapy 
[78]. It is worth noting that M. smithii, like other archaea, is 
intrinsically resistant to antibiotics as a result of its distinctive 
non-bacterial biology [79].
We must acknowledge some limitations of this study: the 
sensitivity of metagenomics as a diagnostic remains uncertain 
and is unlikely to compete with culture – in terms of costs or 
sensitivity – in the detection and characterization of cultur-
able pathogens present in low abundance. In addition, in its 
simplest form, the ability of shotgun metagenomics to link 
mobile elements to the chromosomes from their host cells is 
poor, although proximity linkage approaches might overcome 
this limitation [80].
ConCLuSIonS
Here, we have shown that surveillance of the gut microbiota 
in long-stay ICU patients using shotgun metagenomics is 
capable of detecting episodes of low diversity and pathogen 
domination, as well as providing genome-level resolution of 
colonizing pathogens and evidence of cryptic nosocomial 
transmission. We have also shown that use of meropenem is 
associated with ecological disruption of the gut microbiota. 
These observations pave the way for precise patient-specific 
interventions that protect the gut microbiota (e.g. enhanced 
infection control, tailored use of microbiota-sparing antibi-
otics, oral administration of antibiotic-absorbing charcoal 
or of a beta-lactamase) [81, 82].
Although we failed to find a link between gut microbial 
diversity or pathogen domination of the gut and clinical 
outcomes in our group of ICU patients, such evidence has 
been documented for similar groups of vulnerable patients 
[19, 21, 63], where ecological approaches to restoring gut 
microbial diversity, such as faecal microbiota transplants, 
are under evaluation [16–18, 83, 84]. Similar intervention 
studies – underpinned by the kind of metagenomic surveil-
lance we have established here – are likely to clarify whether 
maintenance or restoration of gut microbial diversity influ-
ences clinical outcomes in long-stay ICU patients.
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